Zeneca's goserelin acetate for breast cancer
NDA supplement filed for implant formulation of goserelin acetate (Zoladex in oral form) in treating advanced breast cancer in premenopausal and perimenopausal women. The supplemental application is based on results of trials involving more than 800 women in North America and Europe. Zeneca says Zoladex "provides response rates and survival benefits comparable to those achieved by other standard treatments such as surgical oophorectomy or irradiation of the ovaries"...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth